Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?

Executive Summary

As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development

You may also be interested in...



Bristol pleads guilty in Plavix anti-trust case

Bristol-Myers Squibb agrees to plead guilty to criminal charges and pay as much as $1 million to settle a federal investigation of the firm's failed efforts to stave off market entry of Apotex's generic version of Plavix. The criminal charges stem from false statements made to the Federal Trade Commission by a former Bristol executive during the agency's antitrust review of an agreement between Bristol and Apotex, which received FDA approval for generic clopidogrel in January 2006. Bristol allegedly made verbal agreements with Apotex that were not included in written documents submitted to FTC (1"The Pink Sheet" March 27, 2006, p. 16). The plea is the culmination of a series of Plavix-related events that included to the ouster of Bristol's then-CEO, Peter Dolan...

Bristol pleads guilty in Plavix anti-trust case

Bristol-Myers Squibb agrees to plead guilty to criminal charges and pay as much as $1 million to settle a federal investigation of the firm's failed efforts to stave off market entry of Apotex's generic version of Plavix. The criminal charges stem from false statements made to the Federal Trade Commission by a former Bristol executive during the agency's antitrust review of an agreement between Bristol and Apotex, which received FDA approval for generic clopidogrel in January 2006. Bristol allegedly made verbal agreements with Apotex that were not included in written documents submitted to FTC (1"The Pink Sheet" March 27, 2006, p. 16). The plea is the culmination of a series of Plavix-related events that included to the ouster of Bristol's then-CEO, Peter Dolan...

Bristol May Be An Acquisition Target Following Entry Of Plavix Generics

The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target

Related Content

UsernamePublicRestriction

Register

PS047004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel